A preliminary investigation of tobacco co-use on endocannabinoid activity in people with cannabis use
Drug and Alcohol Dependence Reports · 2025-09 · 16 · 100369
DOI: 10.1016/j.dadr.2025.100369 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug and Alcohol Dependence Reports, 2025-09. Verfasst von Rachel A Rabin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Integrated Program in Neuroscience, McGill University, Montreal, Canada. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institute of Mental Health, Fonds de recherche du Quebec Sante.
Abstract (Originalsprache)
Tobacco is commonly co-used with cannabis. This is unfortunate because tobacco co-use exacerbates select clinical consequences associated with cannabis use. Evidence demonstrates that low levels of anandamide, a prominent endocannabinoid, correlate with worse clinical outcomes. Fatty acid amide hydrolase (FAAH) degrades anandamide, and greater FAAH levels may underlie poorer clinical outcomes in people who co-use relative to those who use only cannabis. Therefore, we tested whether tobacco co-use increases FAAH levels beyond those associated with cannabis use alone. Cannabis-using participants (N = 13) were parsed into individuals with daily tobacco use (CT, n = 5) and no current tobacco use (CAN, n = 8). We evaluated group differences in FAAH, quantified using positron emission tomography and [11C]CURB, while controlling for sex and FAAH genotype in the prefrontal cortex, hippocampus, thalamus, sensorimotor striatum, substantia nigra, and cerebellum. A significant group x ROI interaction for [11C]CURB λk3 [F(5, 45)= 3.15, p = 0.016] emerged. Bonferroni-corrected post-hoc tests indicated greater FAAH levels in CT compared to CAN in the substantia nigra (p = 0.023, d=1.54) and cerebellum (p = 0.003, d=1.76), while a trend emerged in the sensorimotor striatum (p = 0.054, d=1.33). Preliminary findings suggest that tobacco co-use is associated with elevated FAAH activity relative to cannabis-only use, which may underlie poorer clinical outcomes associated with co-use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Integrated Program in Neuroscience, McGill University, Montreal, Canada.
- Department of Psychiatry, McGill University, Montreal, Canada.
- Douglas Mental Health University Institute, Montreal, Canada.
Förderung
- National Institute of Mental Health
- Fonds de recherche du Quebec Sante
Zitieren
APA
Rabin, R. A., Farrugia, J., Garani, R., Mizrahi, R., & Rusjan, P. (2025). A preliminary investigation of tobacco co-use on endocannabinoid activity in people with cannabis use. Drug and Alcohol Dependence Reports, 16, 100369. https://doi.org/10.1016/j.dadr.2025.100369
Vancouver
Rabin RA, Farrugia J, Garani R, Mizrahi R, Rusjan P. A preliminary investigation of tobacco co-use on endocannabinoid activity in people with cannabis use. Drug and Alcohol Dependence Reports. 2025;16:100369. doi:10.1016/j.dadr.2025.100369
BibTeX
@article{Rabin2025,
author = {Rabin, Rachel A and Farrugia, Joseph and Garani, Ranjini and Mizrahi, Romina and Rusjan, Pablo},
title = {A preliminary investigation of tobacco co-use on endocannabinoid activity in people with cannabis use},
journal = {Drug and Alcohol Dependence Reports},
year = {2025},
volume = {16},
pages = {100369},
doi = {10.1016/j.dadr.2025.100369}
}
EUVIMED